首页> 美国卫生研究院文献>Scientific Reports >Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China
【2h】

Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China

机译:中国西部多民族地区乙肝病毒基因型和抗病毒药物耐药性的流行病学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatitis B virus (HBV) infection is a critical global health issue and moderately epidemic in Western China, but HBV molecular epidemiology characteristics are still limited. We conducted this study to investigate HBV genotypes and antiviral resistant mutations in this multi-ethnic area. A total of 1316 HBV patients were recruited from four ethnic groups from 2011 to 2013. Genotypes and resistant mutations were determined by Sanger sequencing. Four genotypes (B, C, D and C/D) were identified. Genotype B and C were common in Han population, while genotype D was predominant in Uygurs. Genotype C was the major genotype in both Tibetans and Yis, and recombinant C/D was found in Tibetans only. Lamivudine resistance was common in all populations, especially in Hans with prevalence of 42.8%. Entecavir resistance was barely observed regardless of ethnicity. Genotype C isolates had higher rates of rtA181T/V than genotype B (13.5% vs. 5.1%, P < 0.001), in accordance with higher prevalence of resistance to adefovir (20.0% vs. 9.5%, P < 0.001). While incidence of resistant mutations to other drugs and clinical factors showed no difference among different genotypes. HBV genotypes and resistance-conferring mutations had different geographic and demographic distributions in Western China, which provided molecular epidemiology data for clinical management.
机译:乙型肝炎病毒(HBV)感染是一个重要的全球性健康问题,在中国西部是中度流行病,但HBV分子流行病学特征仍然有限。我们进行了这项研究,以调查这个多民族地区的HBV基因型和抗病毒耐药性突变。 2011年至2013年,共从四个种族中招募了1316例HBV患者。通过Sanger测序确定了基因型和耐药突变。确定了四种基因型(B,C,D和C / D)。基因型B和C在汉族人群中很常见,而基因型D在维吾尔族中占主导地位。基因型C是藏族和彝族的主要基因型,重组C / D仅在藏族中发现。拉米夫定耐药性在所有人群中都很普遍,特别是在汉斯人群中,患病率为42.8%。无论种族如何,几乎都观察不到恩替卡韦耐药。基因型C分离株的rtA181T / V率比基因型B高(13.5%比5.1%,P <0.001),这是由于对阿德福韦的耐药率更高(20.0%比9.5%,P <0.001)。尽管对其他药物和临床因素的耐药突变发生率在不同基因型之间没有差异。乙型肝炎病毒基因型和赋予耐药性的突变在中国西部地区具有不同的地理和人口分布,为临床管理提供了分子流行病学数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号